Trials / Completed
CompletedNCT00430365
Maintenance Therapy Using Lenalidomide in Myeloma
Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 614 (actual)
- Sponsor
- University Hospital, Toulouse · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Maintenance treatment of myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lenalidomide | oral drug |
| DRUG | placebo | oral placebo |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2017-09-01
- Completion
- 2018-09-01
- First posted
- 2007-02-01
- Last updated
- 2026-04-06
Locations
77 sites across 3 countries: Belgium, France, Switzerland
Source: ClinicalTrials.gov record NCT00430365. Inclusion in this directory is not an endorsement.